53 results
8-K
EX-99.1
JNCE
Jounce Therapeutics Inc
7 Nov 19
Jounce Therapeutics Reports Third Quarter 2019 Financial Results
6:43am
as the dosing and sequencing strategy for vopratelimab in our ongoing EMERGE Phase 2 trial, at the SITC 2019 Annual Meeting this weekend,” said Richard … of vopratelimab and a PD-1 inhibitor. The first of the induction studies, EMERGE, is underway.
Dosing and sequencing strategy for EMERGE Phase 2 trial
8-K
EX-99.1
JNCE
Jounce Therapeutics Inc
4 May 21
Jounce Therapeutics Reports First Quarter 2021 Financial Results
7:09am
development acumen needed to move beyond our next set of inflection points. We remain committed to our core strategy of translational science, biomarker … biomarker, and patient selection strategy of the SELECT trial.
JTX-1811 (CCR8)
Progressed JTX-1811 toward IND: Jounce continues to progress JTX-1811
8-K
EX-99.1
JNCE
Jounce Therapeutics Inc
13 Jan 20
Results of Operations and Financial Condition
8:01am
ICONIC Data Leadse to Unique Dosing Strategy g a 60 g n E saturation of signaling t 40 Target Engagement from ICONIC Patients e g r a 0.03 mg/kg vopra … 30 30 40 40 50 50 0.3 mg/kg vopra + ipi DayDs aoyns S otund Sytudy New Strategy: Optimize Dosing for Pulsed Periods of Target Engagement 12 | Jounce
8-K
EX-99.1
JNCE
Jounce Therapeutics Inc
7 Apr 20
Regulation FD Disclosure
7:55am
.
Unique Dosing Strategy for EMERGE and100 SELECT t 80 n e saturation of receptor m e g 60 a g Pulsatile Dosing of Vopra May Be Preferable n Lowersa … + ipi 0 0 10 20 30 40 50 0.3 mg/kg vopra + ipi 0.3 mg/kg vopra + ipi 0 10 Da2y0s on St3u0dy 40 50 Days on Study New Dose Strategy: Pulsed Periods
S-1
JNCE
Jounce Therapeutics Inc
30 Dec 16
IPO registration
12:00am
to match the right therapy to the right patient. Our strategy is to create immunotherapies targeting a variety of the diverse cellular components … and/or niche subsets within indications to inform our clinical strategy. By taking this biomarker-driven approach, which supports enriched-enrollment
10-K
1cutndhbm
10 Mar 17
Annual report
12:00am
10-Q
ymmv1ycmaz
9 May 17
Quarterly report
12:00am